Company Overview
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.
Why Investors Should Care
Trades at a P/E of 15.1, below the sector median of 24.8.
Recent Developments
- 5-Year Trend Long-term compounding — profit CAGR -9.9%.
Growth & Price Performance
Compounded Profit Growth
| 5 Years: | -9.87% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +68.84% |
| 6 Months: | -5.47% |
| 3 Months: | +6.76% |
| 1 Month: | -6.92% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)44.01 · Neutral
P/E of 15.12 is below the sector median of 24.83 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Earnings shrank at -9.9% CAGR over 5 years.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | SABS SAB Biotherapeutics, Inc. PHARMA | 3.63 | 15.12 | $330.28M | 0.00% | -30.19% | -11.27% | - | -9.87% |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 16.93M | 18.21M | 14.68M | 11.80M | 6.35M | 3.59M | 581.10K | 85.52K | 1.27M | 944.58K | 263.14K | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | 10.77M | 9.73M | 12.68M | 15.77M | 20.00M |
| Operating Income | 813.92K | -2.87M | -3.99M | -6.71M | -6.54M | -7.81M | -7.40M | -6.48M | -5.32M | -11.39M | -10.20M | -11.31M | - | -10.77M | -9.73M | -12.68M | -15.77M | -20.00M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | -4.35M | -9.28M | 46.25M | -16.03M | -18.05M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | 69.56K | 64.34K | 43.29K | 63.46K | 62.74K |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | -5.20M | -10.11M | 45.45M | -16.86M | -18.87M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | 1.41M | -2.94M | -4.06M | 985.86K | -4.78M | -7.08M | -7.35M | -6.88M | -5.10M | -5.03M | -7.34M | -10.35M | - | -5.20M | -10.11M | 45.45M | -16.86M | -18.87M |
| Diluted EPS | 0.05 | -0.11 | -0.16 | 0.02 | -0.11 | -0.16 | -1.46 | -1.36 | -0.97 | -0.54 | -0.79 | -1.12 | - | -0.56 | -1.09 | -0.21 | - | -0.35 |
| R&D Expense | 12.78M | 18.68M | 15.07M | 13.32M | 8.58M | 7.35M | 4.54M | 3.66M | 4.02M | 8.15M | 6.82M | 7.83M | - | 7.66M | 7.00M | 8.97M | - | 13.40M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | 55.24M | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| Operating Expenses | - | - | 28.92M | 38.08M | 42.91M | 48.95M |
| Operating Income | 20.56M | - | -28.92M | -38.08M | -42.91M | -48.95M |
| EBITDA | - | - | -15.12M | -38.13M | -28.99M | 16.60M |
| Interest Expense | - | - | 301.58K | 315.28K | 318.40K | 240.66K |
| Pretax Income | - | - | -18.72M | -42.19M | -34.11M | 13.27M |
| Tax Provision | - | 0 | 25.63K | 0 | - | - |
| Net Income | 20.12M | - | -18.74M | -42.19M | -34.11M | 13.27M |
| Diluted EPS | 0.74 | - | -4.31 | -7.64 | -3.68 | -0.79 |
| R&D Expense | 27.91M | 57.18M | 36.44M | 16.52M | 30.25M | 34.35M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Mar 2022 | Jun 2022 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 56.54M | - | 68.49M | 59.41M | 50.90M | 83.94M | 44.20M | 172.81M |
| Current Assets | - | - | - | - | - | 22.10M | 58.91M | 23.79M | 101.05M |
| Cash & Equivalents | - | 12.61M | - | 22.41M | 16.62M | 15.05M | 56.57M | 8.90M | 10.50M |
| Inventory | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | 8.01M | - | - | 5.56M | 0 | - | - |
| Total Liabilities | - | 17.53M | - | 27.23M | 22.29M | 19.85M | 26.64M | 18.23M | 21.32M |
| Current Liabilities | - | 11.06M | - | 19.27M | 16.39M | 14.99M | 10.81M | 7.98M | 10.68M |
| Long Term Debt | - | - | - | - | - | 541.64K | - | - | - |
| Total Debt | - | - | - | - | - | 5.93M | 5.91M | 4.67M | 5.95M |
| Total Equity | 7.69M | 39.01M | - | 41.26M | 37.12M | 31.06M | 57.30M | 25.97M | 151.49M |
| Shares Outstanding | - | - | - | - | - | 5.09M | 9.28M | 9.34M | 47.66M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | 10.00M | - | -23.46M | -25.12M | -34.29M | -44.78M |
| Investing Cash Flow | -12.72M | - | -2.09M | -152.70K | -11.96M | -121.71M |
| Financing Cash Flow | 8.98M | - | 1.05M | 66.77M | -1.17M | 168.30M |
| Capital Expenditure | -12.73M | - | -2.17M | -197.15K | -337.26K | -933.16K |
| Free Cash Flow | -2.73M | - | -25.63M | -25.32M | -34.63M | -45.71M |
| Net Change in Cash | - | - | -24.50M | 41.50M | -47.43M | 1.82M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - |
| Operating Margin % | 37.2% | - | - | - | - | - |
| Net Margin % | 36.4% | - | - | - | - | - |
| ROE % | 51.6% | - | -60.3% | -73.6% | -131.3% | 8.8% |
| ROCE % | 45.2% | - | -80.5% | -52.1% | -118.5% | -30.2% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Caligan Partners, LP | 8.76% | 7.97M | $27.96M |
| 2 | Vivo Capital, LLC | 8.02% | 7.30M | $25.62M |
| 3 | Perceptive Advisors Llc | 7.28% | 6.63M | $23.26M |
| 4 | Adage Capital Partners GP L.L.C. | 7.04% | 6.41M | $22.48M |
| 5 | RA Capital Management, L.P. | 4.84% | 4.40M | $15.45M |
| 6 | Balyasny Asset Management LP | 4.13% | 3.76M | $13.20M |
| 7 | Blackrock Inc. | 3.37% | 3.07M | $10.76M |
| 8 | Vanguard Capital Management LLC | 3.27% | 2.97M | $10.43M |
| 9 | Commodore Capital Lp | 3.15% | 2.87M | $10.07M |
| 10 | Millennium Management Llc | 3.02% | 2.75M | $9.65M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for SABS
We Think SAB Biotherapeutics (NASDAQ:SABS) Needs To Drive Business Growth Carefully - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxQQ2FVcEIwYlRuWmFaMEtjNFdoTDRYcnZiT2ZhSlJVUUh3TVNjRU9mZEdJei0yWEdHVC01ZTNWWUdVM0RsRXhteElHSVNIYWVQZGpiQnpWUDVYbmZVX0NWNndGYWRXRXFTREZDaFFDbndJbkJLX01QRURoMGZubkotSE1iU3ZyZUR6ZXdmdz…
SABS Forecast — Price Target — Prediction for 2027 - tradingview.com
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE81OVhYWXpFZzhFYzBoYWd4WXc3S0VVempvT1BzNVB1dDRPM2RuYkJvYWRhSGtTSWZ4ekFVS0FOSENmWml0eDRHYUtqdWh3RkptU3FjcnhrZGJIX2pBU2Mzd3pzU3ROSVFlbTZ3R1ZSQ293SUR2SGFiR2h3?oc=5" target="_blank">SAB…
$SABS ($SABS) Releases Q1 2026 Earnings - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMihwFBVV95cUxNUThfbnJtQ0dPR2ROcHFIRkk4QnRPLW51X3lTaHdGU1FPSFdUby10ZzhTZTRldFpyTmhBbFBQTkxQdzgxeHBmT1dqdEJZLVJmSFh3UnJ3X1d1bnIyakpLNnNhZWgtYzc0SkI0VUVaNEZ1di1mN2NNZmlPZTZMeWpfYlpBelZIZFU?oc=5" …
Caligan Partners (SABS) discloses 7.97M SAB Biotherapeutics shares in amended 13G - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxQY2c4YUV6Y3pCbGQ2MnNtaUZMRjhsRWxreWNMSGlPRmdCS0M1bGxyRy1POHNnTUJwWFBjNTV5Q01TZUM4MFlmMDRrQVEtM1ppUkFMcUwwMGJjMHpYc3BoczZxV21LRGlNcndpaEdmNks5VlR1cVh1d0xLZ0U5SWdKcWxpeS1najhPOE1zak…
SAB Biotherapeutics Looks Undervalued If SAB-142 Delivers In Type 1 Diabetes - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxPdXYtRGl6NTZ0aV8wQWxiY0ZwaVFTTzRZbkxLcnNFRnMyWmdrMVFEaDJjdHlWWVNZeEJXT0VqU19QVHBlWTNBV29EX182REkteG1rcm5ZTldaZzBhZDlLRkJ0UW1ELUM3T08tLVluN1VsYS01X29NVU5adkxiS1Q1cnlUYzI2X0xmdEQwUk…
SAB BIO Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewswire
<a href="https://news.google.com/rss/articles/CBMi6gFBVV95cUxNNlJsOWRMeHQtdUZOczhxaklHYnlYZWU1c0sza3RaOUpJaXpvV2dlUGdneXAtMUxJUjI1b3ZNWngzQmlmMGItZ1VWMjJyWENSQlh3N0VhQjF5TzlfQXNocDV4OHVvaUs2SGVNWjV2ZHQxRDlWWHItMkZQR2xPc0hhR1Q0c3ZNSUVreVYtd1…
SABS — Frequently Asked Questions
What is the current share price of SAB Biotherapeutics, Inc. (SABS)?
As of 2026-09-19 21:16 PDT, SAB Biotherapeutics, Inc. (SABS) trades at $3.63 on NasdaqCM. Its 52-week range is $1.95 to $4.59.
What is the market capitalisation of SABS?
SAB Biotherapeutics, Inc. (SABS) has a market capitalisation of $330.28M on NasdaqCM.
What is the P/E ratio of SABS?
SABS trades at a trailing price-to-earnings (P/E) ratio of 15.12. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 1.36.
What is the return on equity (ROE) of SABS?
SABS has a return on equity (ROE) of -11.27%. Its return on capital employed (ROCE) is -30.19%.
Is SABS a good stock to buy?
This page provides a data-driven analysis of SAB Biotherapeutics, Inc. (SABS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.